Short answer
Bausch Health Companies Inc (BHC) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2.9B (up 9.7% year over year) with net income of $436M.
Q3 2026 key financials · XBRL
- Revenue
- $2.9B
- +9.7% YoY · +3.1% QoQ
- Net income
- $436M
- +143.6% YoY · +69.0% QoQ
- Operating margin
- 33.4%
- EPS (diluted)
- $1.17
- +143.8% YoY · +67.1% QoQ
Source: XBRL data from the Bausch Health Companies Inc (BHC) Q3 2026 10-Q on SEC EDGAR. USD.
Bausch Health Companies Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2,941M, up 10% YoY from $2,681M, driven by pricing gains and acquisitions
- Operating margin 33.4% vs 23.1% YoY, with operating income $983M vs $619M
- Best segment: Salix revenue $831M, up 16%; worst growth: International revenue $299M, up 5%
- Nine-month operating cash flow $1,714M vs $905M; ending cash $2,488M vs $1,340M
- Near-term headwinds: Xifaxan negotiated pricing effective 2027, generic entry expected 2028, and ongoing tariff and regulatory risks
Risk Factors
- New governance risk: Thomas Appio became Bausch + Lomb interim CEO October 12, 2026
- Management bandwidth risk: Appio’s overlapping CEO roles may create competing demands
- Conflict-of-interest risk: Appio also became Bausch + Lomb chairman in August 2026
- Reputational risk: dual-company responsibilities may create actual or perceived conflicts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.